Defining a COPD composite safety endpoint for demonstrating efficacy in clinical trials: results from the randomized, placebo-controlled UPLIFT® trial

BACKGROUND: Chronic obstructive pulmonary disease (COPD) clinical trials evaluating hard endpoints (mortality, hospitalized exacerbations) require a large number of subjects and prolonged observational periods. We hypothesized that a composite endpoint of respiratory outcomes (CERO) can help evaluat...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Respir Res
Glavni autori: Celli, Bartolomé R., Decramer, Marc, Liu, Dacheng, Metzdorf, Norbert, Asijee, Guus M., Tashkin, Donald P.
Format: Artigo
Jezik:Inglês
Izdano: BioMed Central 2016
Teme:
Research
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC4855862/
https://ncbi.nlm.nih.gov/pubmed/27141828
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12931-016-0361-4
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items